Regeneron Pharmaceuticals, Inc. has announced a change in the timing of its presentation at the Morgan Stanley 23rd Annual Global Healthcare Conference. The company will now present at 7:00 a.m. ET on Monday, September 8, 2025.
The presentation will be available via live webcast, accessible from the “Investors & Media” section of Regeneron’s website at https://investor.regeneron.com/events-and-presentations. Archived replays and transcripts will remain on the company’s site for at least 30 days.
Regeneron is a biotechnology company focused on inventing, developing, and commercializing medicines for people with serious diseases. According to the company, “Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases.”
The company also utilizes proprietary technologies such as VelociSuite to produce fully human antibodies and bispecific antibodies. “We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases,” Regeneron stated.
For further information about Regeneron or updates related to their investor events and scientific advancements, visit www.Regeneron.com or follow their official social media channels.
Contact for Investor Relations:
Ryan Crowe
914.847.8790
ryan.crowe@regeneron.com
